← Upcoming Courses
The Cardio-Renal Metabolic (CRM) Regional Webinar is a CPD training designed to strengthen clinical decision-making at the intersection of cardiology, nephrology, and metabolic care. Participants will review the interdependence of the heart, kidneys, and metabolic pathways and translate guideline recommendations into pragmatic treatment algorithms for patients with multimorbidity (e.g., diabetes, hypertension, atherosclerotic CVD, and CKD).
The programme combines concise talks, case-based application, a high-level panel discussion, and extended Q&A. Sessions will emphasise timely therapy selection, risk stratification, and integrated follow-up.
TOPICS TO BE PRESENTED
- Interplay of Heart-Kidney-Pancreas: Key insights for enhanced patient outcomes.
- Spotlight on the Cardio-Renal-Metabolic aspects: Patient case series
WHY YOU SHOULD ATTEND
- Clarify how cardio-renal-metabolic pathways interact and drive risk across common comorbidities.
- Translate multiple diabetes/CKD/CVD guidelines into a single, actionable care pathway.
- Understand when and how to initiate SGLT2 inhibitors to maximise organ protection and reduce events.
- Work through real-world cases (polypharmacy, eGFR thresholds, albuminuria, cost/access).
- Earn accredited CPD points with practical take-aways you can apply on the next clinic day.
- Engage directly with expert faculty during an extended Q&A and panel discussion.
PROUDLY SPONSORED BY
This is a virtual event scheduled for Friday the 7th of November, 2025 at 15:30 GMT.
Target Audience: Family Medicine Physicians; Internists; Endocrinologists/Diabetologists; Nephrologists; General Practitioners.
Date: Friday, 7th November, 2025
Time: 15:30 GMT (3:30 PM Local Time)
The sessions and Q&A will be moderated by
Dr. Aravind R. Sosale
Consultant Diabetologist
Don’t miss out on this exciting opportunity to elevate your skills and make a lasting impact in CRM!
PARTICIPANT CONSENT AND DATA PRIVACY NOTICE
By registering for the “Cardio-Renal Metabolic (CRM) Regional Webinar #03”, you consent to participate in this training hosted by Continuous Education Services (CES) on behalf of Boehringer Ingelheim (BI) and DP World. Your registration will provide us with the necessary information to facilitate the event and issue CPD accreditation through the Medical and Dental Council (MDC). CES is committed to safeguarding your personal information and will not share any personal data with BI or DP World. Your data will only be shared with the relevant regulatory bodies, such as MDC, solely for accrediting CPD points earned through this training. Participants are free to opt out of the meeting at any time; no further action is required on your part. Your privacy is respected, and your participation will be treated with the highest level of confidentiality.
Overview
Course Description
This succinct CPD session brings together cardiology, nephrology, and metabolic expertise to translate current evidence and guidelines into practical care pathways for multimorbid patients. Through focused talks, real-world cases, and an extended Q&A, participants will examine the heart–kidney–metabolic interplay, refine risk stratification using eGFR and UACR, and clarify when early initiation of SGLT2 inhibitors delivers organ protection and outcome benefits. Faculty will highlight rational combination therapy, safety monitoring, and coordinated follow-up to reduce events and improve quality of life. Designed for family physicians, internists, endocrinologists, nephrologists, and GPs, the programme prioritises immediately actionable skills and accredited learning.
What you will learn
By the end of the webinar, participants should be able to:
1. Explain the bidirectional relationships across the heart–kidney–metabolic axis and their impact on outcomes.
2. Perform risk stratification using eGFR, UACR, blood pressure, and cardiometabolic markers to guide therapy.
3. Apply contemporary diabetes and CKD/CVD guidelines to create streamlined, patient-centred treatment plans.
4. Identify when early initiation of SGLT2 inhibitors is indicated and describe expected cardio-renal benefits.
5. Optimise combination therapy (e.g., RAS blockade, statins, SGLT2i, GLP-1 RA where appropriate) while monitoring safety and contraindications.
6. Manage complex, multi-morbid cases through coordinated follow-up, medication review, and measurable care goals.
Course Content
Lecture Sessions
No session added to this course yet.
Downloadables
No downloadable content added to this course yet.
About Facilitators
- 1 Course on CES
Prof. Ted Wu
MB BS, FRACP, PhD
Director, Diabetes Centre | Senior Staff Specialist, Endocrinology
Royal Prince Alfred Hospital
Prof. Ted Wu is an accomplished endocrinologist and medical educator with extensive experience in diabetes care, clinical research, and professional training. He currently serves as the Director of the Diabetes Centre at Royal Prince Alfred Hospital, where he also holds the position of Senior Staff Specialist in Endocrinology.
View full profile / courses
- 1 Course on CES
Prof. Javed Butler
MBBS, MPH, MBA
President and Chief Research Executive
Baylor Scott and White Research Institute
Prof. Javed Butler is a leading cardiologist and clinical investigator whose work spans patient care, research and health-system leadership. He serves as President of the Baylor Scott & White Research Institute and Senior Vice President of Baylor Scott & White Health in Dallas.
View full profile / courses
